Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
looking good today !!
ROSG +15% had been on my watchlist due to the solid balance sheet and potential but forgot to grab. Nice one.
Big News Out: Granted Patent Allowance!
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors
Date : 01/25/2016 @ 8:00AM
The problem is this Stately, the company financed operations through selling shares, nothing wrong with that, what is wrong they sold shares, then screwed the investors not once but TWICE doing a reverse.
Now they are selling shares again to finance research, treating the stock like an endless piggy bank. With the company likely at least 3 years from turning a profi what is to say they don't do another reverse, or even 3-4 more?
Institutions got burned twice, are they really going to get fooled again?
Just my two cents
Slautherhouse... Just crazy... Ready to add more.
What? Nobody thinks that. Obviously getting a patent approved is actual news and not a pump. The issue is that the company needs to make money, and it's unclear whether or not this actually gets them any closer to being a growing, profitable company.
IMO Seem like peeps are treating this PR as a "pump and Dump". This not good at all. Not good at all.
Yes, I have a buy order also to pick up 25K once the gap is filled. I kept Rosetta on my market watch list every since the last run.
Well i just added 10k. ROSG getting some attention here the last couple of weeks. Volume is good to.
The Gap is almost fill. I just hope the profit taking doesn't scar away potential buyers and investors. Let's see what happen when the gap is fill at 1.03.
Hmm? Back to 1,1
The float is very low. Very Good News Rosetta Genomics.
Great News. Once the gap is close we're going to run hard.
Sorry wrong board. (SNGX)
Just got some at 73 cents.
$ROSG getting some volume/action here at 1.47
Dead cat bounce.
Looks like bad from the past few days action
Yeah, that's what interests me with this company. Thanks, I will check out that site...
Yep. Long time shareholder just waiting for the age of miRNAs to come! For fun go to PubMed at the NCBI web site and search microRNA. Pretty amazing how far they have come.
Rosetta Genomics to Present at the 17th Annual Rodman & Renshaw Global Investment Conference
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in the upcoming 17th Annual Rodman & Renshaw Global Investment Conference being held from September 8-10, 2015 at the St. Regis Hotel in New York City. Ken Berlin, Rosetta’s President and Chief Executive Officer, will present a corporate overview and update on September 10, 2015 at 5:05 p.m. Eastern time.
Anyone out there long on this one?
As predicted sub 3. Was only a matter of time
If you are looking for a flip this isn't it. The company is forecasted by analyst to continue to have loses through at least 2018. There is virtually no institutional investors, they got burned twice by R/S and the company isn't going anywhere without institutional money. The company continues to fund operations through stock sales. No telling where the float/AS will be if and when they ever turn a profit.
Sorry, but if you have some coin to sit for 2-4 years you may get a profit. If you're looking for short term gains I don't think this is it.
Just my opinion
ROSG partner BIOC, Biocept, Conference call.
ROSG & BIOC are two great companies.
Last week BIOC had their Conference Call.
The CEO talked about ROSG in that call.
Here is the link.
http://ir.biocept.com/eventdetail.cfm?EventID=160167
ROSG news and solid premarket trading
Haha no sub 3's it has lower lows i for one am buying on dips these are short term traders holding it down with there flipping it shall go in my opinion much higher growth story here - good luck
Looks like we are destined for sub 3's again. Company stats they will possibly be profitable in late 2017 I believe it was. Not to mention the 500k unrestricted shares I am sure will make it into the market.
Had hopes for this one but it looks like any real gain is a couple of years away....maybe
They burned the investment companies not once but twice with R/S's and I would not expect real money to flow in until they prove they can execute.
The analyst report on ROSG sounds promising. I can't say I understand the science though. Does anyone have insight into the company they just bought?
tia,
Net-Man
ROSG Announces Data Published in Leukemia Research. Broke the 4.00 mark in Pre-Market. Could see a nice run today.
Thanks bud! Good technical analysis info.
$ROSG chart - 50 DMA / 200 DMA $Golden $Cross - candles forming above both levels - nice $Volume - Fast Sto in Bull Zone - RSI hitting the 70 overbought/power zone - MACD Line looks very bullish - MACD Histogram building -
4.00 is a major resistance zone & is the $Key level to turn into support - checkout the Feb. action @ that level - $ROSG broke 4.00 resistance w/ a close above on Feb. 17th, but was unable to turn that level into support - the share price responded by consolidating - the 100 DMA @ 2.96 support level held & a rally followed -
The $KEY now is to turn the 50 & 200 DMA's into support along w/ the 4.00 zone - when candles form ABOVE 4.00 it will be Bullish -
ROSG ....Here we go $$$$$.
Up in PM.
It's moving all right, right back down
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1914
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators |
http://www.rosettagenomics.com/
http://finance.yahoo.com/q/ks?s=ROSG
Rosetta Genomics, Ltd., a biotechnology company, develops microRNA-based diagnostic and therapeutic products. MicroRNAs are naturally expressed or produced using instructions encoded in DNA, and could be used in regulating protein production. The company, using its intellectual property, collaborative relationships, and microRNAs, has initiated programs to develop microRNA-based diagnostic and therapeutic products for various cancers and infectious diseases. It primarily focuses on prostate, lung, colorectal, breast, and bladder cancers. Rosetta Genomics is also developing a diagnostic test to identify the origin of the primary tumor in metastatic cancers of unknown primary site. In addition, it is collaborating with others on the development of microRNA-based therapeutic products for the treatment of liver cancer and infectious diseases. The company has collaboration and license agreements with Asuragen, Inc.; Isis Pharmaceuticals, Inc.; Hadasit Medical Research Services and Development, Ltd.; U.S. Genomics, Inc.; The Rockefeller University; Max Planck Innovation GmbH; Johns Hopkins University; Columbia University; and Tel Hashomer Medical Research Infrastructure and Services, Ltd. Rosetta Genomics was founded in 2000 and is based in Rehovot, Israel.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |